Since the publication of the guidelines for the assessment and management of non alcoholic
fatty liver disease (NAFLD) by the Asia–Pacific Working Party on NAFLD in 2007, 1 our …

How to assess efficacy of interventions. In clinical practice, and particularly among those
who appear to have mild liver disease, it may be sufficient to note changes (normalization) of …

Background Glecaprevir and pibrentasvir are direct-acting antiviral agents with
pangenotypic activity and a high barrier to resistance. We evaluated the efficacy and safety …

Background In phase 2 trials, treatment with the combination of the nucleotide polymerase
inhibitor sofosbuvir and the NS5A inhibitor velpatasvir resulted in high rates of sustained …

Background & Aims Hepatitis C virus (HCV) therapy that is highly efficacious, pangenotypic,
with a high barrier to resistance and short treatment duration is desirable. The efficacy and …

Outcomes of hepatitis C virus (HCV) infection and treatment depend on viral and host
genetic factors. Here we use human genome-wide genotyping arrays and new whole …

The aim of this paper is to review and up to date the prevalence of hepatitis C virus (HCV)-
associated non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis …

Non‐alcoholic fatty liver disease (NAFLD) has become the leading cause of chronic liver
disease, affecting approximately 25% of the world's population. Recently, because of the …

Hepatitis C virus (HCV) genotype (gt) 3 is highly prevalent globally, with non‐gt3a subtypes
common in Southeast Asia. Resistance‐associated substitutions (RASs) have been shown …

Today, with the introduction of interferon-free direct-acting antivirals and outstanding
progresses in the prevention, diagnosis and treatment of hepatitis C virus (HCV) infection …